Lord, Abbett & Co
JBIO

Lord, Abbett & Co’s Jade Biosciences JBIO Stock Holding History

Lord, Abbett & Co’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.04M Buy
+226,606
New +$4.73M 0.01% 477

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lord, Abbett & Co's JBIO Position: Q2 2026 in Review

Lord, Abbett & Co opened a new position in Jade Biosciences (JBIO) in Q2 2026: 226,606 shares worth $5.04M. The stake represents 0.01% of the portfolio and ranks #477 among its holdings.

154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Lord, Abbett & Co held 226,606 shares of Jade Biosciences worth $5.04M as of Q2 2026.
  • Jade Biosciences was a new Lord, Abbett & Co position in Q2 2026.
  • Jade Biosciences made up 0.01% of Lord, Abbett & Co's portfolio in Q2 2026, its #477 holding.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.